Datar Cancer Genetics Limited
Dr Stefan Schuster is a specialist for liquid biopsies and published numerous articles, attended several congresses and held successfully lectures in this field. Since 2019 he is the Managing Director Europe at Datar Cancer Genetics ltd and responsible for the development of the European market. He started his career at SIMFO GmbH (Germany) as assistant to the board in 2013. In 2015 he joined the board of management of SIMFO GmbH as Head of Business Development, responsible for scientific collaborations and economic partnerships worldwide.
He finished his PhD in 2013 developing and validating assays to research GPCRs at the University of Erlangen, Germany, at the Institute of Medicinal Chemistry. He studied pharmacy at the University of Erlangen from 2003 to 2007.
Clinical Utility of Liquid Biopsy in Brain Tumors
Various multi coordinate, blood-based gene interrogation approaches evaluate tumor biomarkers such as ctDNA, mRNA, miRNA released by tumor cells, which contain extensive representations of variants present in the tumor, allowing precise non-invasive monitoring of cancer in real time. Gliotrack™ offers coverage on all relevant molecular biomarkers, and is beneficial for patients with suspected glioma/glioblastoma and who are unfit for biopsy, diagnosed glioma patients, to monitor disease progression and detect recurrence at the earliest.
EVEN MORE SEMINARS
Geeta Shetty, MBBS, MS(Gen.Surg), DNB(Gen.Surg), DM, FRCS(Gen.Surg) Sandwell and West Birmingham Hospitals NHS Trust
Chest Wall Perforator Flaps for Partial Breast Reconstruction
Lucinda Billingham University of Birmingham - Cancer Research Clinical Trials Unit
National Lung Matrix Trial: testing multiple novel targeted treatments
Dr Shanmugasundaram Ramkumar University Hospital Southampton NHS Foundation Trust
Radiotherapy developments in management of recurrent rectal cancers
Professor Jayant Vaidya University College London
Targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations